Meera Tugnait

1.9k total citations
25 papers, 912 citations indexed

About

Meera Tugnait is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Meera Tugnait has authored 25 papers receiving a total of 912 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Pharmacology and 7 papers in Oncology. Recurrent topics in Meera Tugnait's work include Pharmacogenetics and Drug Metabolism (8 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Meera Tugnait is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Meera Tugnait collaborates with scholars based in United States, United Kingdom and Germany. Meera Tugnait's co-authors include Narayana I. Narasimhan, David Kerstein, David J. Dorer, Edward M. Hawes, Frank G. Haluska, Vincent Mascitti, Lyudmila Bazhenova, Ravi Salgia, David Ross Camidge and Alice T. Shaw and has published in prestigious journals such as Nature Medicine, Blood and The Lancet Oncology.

In The Last Decade

Meera Tugnait

23 papers receiving 897 citations

Peers

Countries citing papers authored by Meera Tugnait

Since Specialization

Citations

This map shows the geographic impact of Meera Tugnait's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meera Tugnait with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meera Tugnait more than expected).

Fields of papers citing papers by Meera Tugnait

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meera Tugnait. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meera Tugnait. The network helps show where Meera Tugnait may publish in the future.

Co-authorship network of co-authors of Meera Tugnait

This figure shows the co-authorship network connecting the top 25 collaborators of Meera Tugnait. A scholar is included among the top collaborators of Meera Tugnait based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meera Tugnait. Meera Tugnait is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EMPOWERing the Next-Generation: A Phase 2 Program to Evaluate Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM), for the Treatment of Schizophrenia 2024 ·CNS Spectrums ·(unknown), (unknown), Koji Takahashi, (unknown), Meera Tugnait, (unknown), Ih Chang, (unknown), Pamela Perry, Matthew Leoni, Raymond Sanchez	0
2	Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach 2024 ·CPT Pharmacometrics & Systems Pharmacology ·Michael J. Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana I. Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta	2
3	Brigatinib pharmacokinetics in patients with chronic hepatic impairment 2023 ·Investigational New Drugs ·Michael J. Hanley, David Kerstein, Meera Tugnait, Narayana I. Narasimhan, Thomas Marbury, Karthik Venkatakrishnan, Neeraj Gupta	3
4	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial 2021 ·Nature Medicine ·Daniel J. DeAngelo, Deepti Radia, Tracy I. George, William A. Robinson, Albert Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott F. Winton, Hans‐Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica N Evans, Huimin Lin, Brenton G. Mar, Srđan Verstovšek, Michael W. Deininger, Jason Gotlib	88
5	Effect of severe renal impairment on the pharmacokinetics of brigatinib 2021 ·Investigational New Drugs ·Neeraj Gupta, Michael J. Hanley, David Kerstein, Meera Tugnait, Narayana I. Narasimhan, Thomas Marbury, Karthik Venkatakrishnan	7
6	Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers 2019 ·Clinical Pharmacology in Drug Development ·Meera Tugnait, Neeraj Gupta, Michael J. Hanley, Daryl Sonnichsen, David Kerstein, David J. Dorer, Karthik Venkatakrishnan, Narayana I. Narasimhan	19
7	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial 2016 ·The Lancet Oncology ·Scott Gettinger, Lyudmila Bazhenova, Corey J. Langer, Ravi Salgia, Kathryn A. Gold, Rafael Rosell, Alice T. Shaw, Glen J. Weiss, Meera Tugnait, Narayana I. Narasimhan, David J. Dorer, David Kerstein, Victor M. Rivera, Timothy Piers Clackson, Frank G. Haluska, David Ross Camidge	261
8	PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy 2013 ·Frontiers in Pharmacology ·Stephen Orena, Tristan S. Maurer, Li She, (unknown), (unknown), (unknown), Paula M. Loria, Mary Ellen Banker, Meera Tugnait, Carlin V. Okerberg, (unknown), Carine M. Boustany‐Kari	44
9	Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects 2012 ·Drug Metabolism and Disposition ·Zhuang Miao, Gianluca Nucci, Neeta B. Amin, Raman Sharma, Vincent Mascitti, Meera Tugnait, Alfin D. N. Vaz, Ernesto Callegari, Amit S. Kalgutkar	102
10	Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology 2011 ·The AAPS Journal ·Tristan S. Maurer, Avijit Ghosh, Nahor Haddish‐Berhane, Aarti Sawant‐Basak, Carine M. Boustany‐Kari, Li She, Michael T. Leininger, Tong Zhu, Meera Tugnait, Xin Yang, Emi Kimoto, Vincent Mascitti, Ralph P. Robinson	28
11	Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus 2011 ·Drug Metabolism and Disposition ·Amit S. Kalgutkar, Meera Tugnait, Tong Zhu, Emi Kimoto, Zhuang Miao, Vincent Mascitti, Xin Yang, Beijing Tan, Robert L. Walsky, (unknown), Bo Feng, Ralph P. Robinson	59
12	The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism 2011 ·Journal of Translational Medicine ·(unknown), Vaishali Sahasrabudhe, Kevin Sweeney, Meera Tugnait, Amanda King‐Ahmad, (unknown), Paula M. Loria, Mary Ellen Banker, David W. Piotrowski, Carine M. Boustany‐Kari	48
13	Metabolism and transporter-mediated drug–drug interactions of the endothelin-A receptor antagonist CI-1034 2005 ·Chemico-Biological Interactions ·Jasminder Sahi, Michael Sinz, Scott Campbell, (unknown), Xianxian Zheng, Kelly Rose, Shamsi Raeissi, Muhammed F. Hashim, (unknown), Sonia M. de Morais, Christopher B. Black, Meera Tugnait, L Keller	22
14	UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES 2005 ·Drug Metabolism and Disposition ·Jonathan Bauman, Theunis C. Goosen, Meera Tugnait, Vincent Peterkin, Susan Hurst, (unknown), Mark A. Milad, Michael H. Court, J. Andrew Williams	16
15	Application of semi-automated metabolite identification software in the drug discovery process for rapid identification of metabolites and the cytochrome P450 enzymes responsible for their formation 2002 ·Journal of Pharmaceutical and Biomedical Analysis ·Ragu Ramanathan, Donald L. McKenzie, Meera Tugnait, (unknown)	9
16	The metabolism of 4-trifluoromethoxyaniline and [13C]-4-trifluoromethoxyacetanilide in the rat: detection and identification of metabolites excreted in the urine by NMR and HPLC-NMR 2002 ·Journal of Pharmaceutical and Biomedical Analysis ·Meera Tugnait, Eva M. Lenz, (unknown), M. Hofmann, Manfred Spraul, John C. Lindon, Jeremy K. Nicholson, Ian D. Wilson	13
17	The metabolism of 2-trifluormethylaniline and its acetanilide in the rat by 19F NMR monitored enzyme hydrolysis and 1H/19F HPLC-NMR spectroscopy 2002 ·Journal of Pharmaceutical and Biomedical Analysis ·Meera Tugnait, Eva M. Lenz, M. Hofmann, Manfred Spraul, Ian D. Wilson, John C. Lindon, Jeremy K. Nicholson	7
18	Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine 1999 ·Chemico-Biological Interactions ·Meera Tugnait, Edward M. Hawes, (unknown), Michel Eichelbaum, (unknown)	50
19	N-oxygenation of clozapine by flavin-containing monooxygenase. 1997 ·PubMed ·Meera Tugnait, Edward M. Hawes, (unknown), Allan E. Rettie, Robert L. Haining, K.K. Midha	59
20	NMR-monitored solid-phase extraction of phenolphthalein glucuronide on phenylboronic acid and C18 bonded phases 1991 ·Journal of Pharmaceutical and Biomedical Analysis ·Meera Tugnait, (unknown), Ian D. Wilson, Jeremy K. Nicholson	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact